Komori
Daiichi Sankyo (4568) · FactFirst stated

Expiration of the VIMPAT Japan Sales and Co-Promotion Agreement

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Termination of the Vimpat Japan distribution and co-promotion agreement with UCB BiopharmaA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2027-H1First statedAnnual report

    「Exclusive sales and co-promotion of the company’s epilepsy treatment Vimpat in Japan Upfront payment Milestones From November 2014 To 10 years after launch (Note) The agreement ended upon expiration of its term on 30 August 2026.」

    The exclusive sales and co-promotion agreement for Vimpat in Japan with UCB Biopharma Sprl ended on 30 August 2026 upon expiration of its 10-year term after launch.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Daiichi Sankyo yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expiration of the VIMPAT Japan Sales and Co-Promotion Agreement | DAIICHI SANKYO COMPANY,LIMITED (4568) | Komori